Lung Cancer

How Long to Continue Immunotherapy

Immunotherapy and Brain Metastatic Lung Cancer

PD-L1 Less Than 49%: Available Treatments

Progression on Immunotherapy: Treatment Approach

Therapy Approach for PD-L1 Over 50% Lung Cancer

Work-Up and Management of Nondriver Metastatic Lung Cancer

Adjuvant Osimertinib Succeeds in Phase III ADAURA Trial in EGFR+ NSCLC

Managing Lung Cancer Patients Through the COVID-19 Pandemic: What to Know

The phase III ADAURA trial of adjuvant osimertinib in patients with EGFR mutation–positive non–small cell lung cancer has been unblinded due to “overwhelming efficacy.”

By OncLive Staff

FDA Grants Nivolumab/Ipilimumab Plus Chemo Priority Review in Frontline NSCLC

Join top leaders in the lung cancer field as they share their insights on COVID-19 and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system on Thursday, May 14, 2020 at 8 PM EST.

Dr. Merritt on Robotic Lobectomy Versus VATS and Open Thoracotomy in NSCLC

April 8th 2020

The FDA has granted a priority review designation to nivolumab plus ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer.

By Robert E. Merritt, MD, FACS

April 7th 2020

Robert E. Merritt, MD, FACS, discusses the long-term oncologic outcomes of robotic lobectomy versus video-assisted thoracoscopic surgery and open thoracotomy in early-stage non-small-cell lung cancer.

Brigatinib Approved in Europe for Frontline ALK+ NSCLC

Weekly Webinar Series Part 6: Managing Lung Cancer Patients Through the COVID-19 Pandemic

April 6th 2020

The European Commission has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.

By OncLive Staff

April 6th 2020

In part 6 of our weekly COVID-19 Webinar Series, our panel of experts will share the latest updates and insights on the novel coronavirus. Join us Wednesday, April 29, 2020 at 8 PM EST.

Dr. Bertino on Frontline Dacomitinib in Metastatic EGFR+ NSCLC

By Erin M. Bertino, MD

April 2nd 2020

Erin M. Bertino, MD, discusses the use of dacomitinib (Vizimpro) in the treatment of patients with non–small cell lung cancer with EGFR mutations and its place among other available EGFR TKIs.

Cancer Vaccine Hits Early Benchmark in NSCLC, But COVID-19 Halts Phase III Trial

Dr. Socinski on Recommendations for Molecular Testing in Lung Cancer

April 2nd 2020

OSE-2101 met the primary endpoint in the predefined Step-1 analysis of the phase III Atalante 1 trial in patients with HLA-A2 positive non–small cell lung cancer after failure of anti–PD-1/PD-L1 agents.

By Mark A. Socinski, MD

March 31st 2020

Mark A. Socinski, MD, discusses his recommendations for conducting molecular testing in lung cancer.

Dr. Chen on the Impact of the Pivotal IMpower133 Trial on SCLC

By Hui-Zi Chen, MD, PhD

March 31st 2020

Hui-Zi Chen, MD, PhD, discusses how the IMpower133 trial has helped to propel the field of small-cell lung cancer forward.

RET Inhibition Research: Next Steps

The Future of RET Inhibition in Clinical Practice

RET Inhibitors in Development

Effect of NGS Wait Time on Decision Making

Targeted Therapy Benefit for Actionable Mutations

The Impact of Upfront NGS Testing on Overall Outcomes

The Importance of NGS Testing in NSCLC

Multikinase TKI Toxicity Profile

The Role of Multikinase TKIs for NSCLC

MOA and Rationale for RET Inhibitor Development

The Importance of Targeting RET in NSCLC

Trastuzumab Deruxtecan Shows Promise Beyond Breast and Gastric Tumors

By Jessica Hergert

FDA Approves Durvalumab for Frontline Small Cell Lung Cancer

Fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody–drug conjugate, demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types.

By Gina Columbus